HHS awarded Merck $1.3B for vaccine purchase, highlighting significant investment in public health

Contract Overview

Contract Amount: $1,317,743,050 ($1.3B)

Contractor: Merck Sharp & Dohme Corp.

Awarding Agency: Department of Health and Human Services

Start Date: 2007-04-16

End Date: 2008-06-01

Contract Duration: 412 days

Daily Burn Rate: $3.2M/day

Competition Type: FULL AND OPEN COMPETITION

Number of Offers Received: 1

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: TAS::75 0512::TAS PURCHASE OF VACCINE FOR CHILDREN

Place of Performance

Location: ATLANTA, DEKALB County, GEORGIA, 30329

State: Georgia Government Spending

Plain-Language Summary

Department of Health and Human Services obligated $1.32 billion to MERCK SHARP & DOHME CORP. for work described as: TAS::75 0512::TAS PURCHASE OF VACCINE FOR CHILDREN Key points: 1. The contract represents a substantial federal investment in ensuring access to essential vaccines. 2. Analysis of pricing and value for money requires comparison with similar bulk vaccine procurements. 3. The 'DEFINITIVE CONTRACT' award type suggests a commitment to a specific supplier for a defined period. 4. Performance context is crucial to understand if the vaccine met public health needs and demand. 5. This procurement falls within the broader Healthcare sector's focus on disease prevention and management. 6. The contract's value indicates a significant portion of federal spending dedicated to vaccine acquisition.

Value Assessment

Rating: fair

Benchmarking the value of this $1.3 billion vaccine purchase against other large-scale public health procurements is challenging without specific unit cost data and market comparisons. The 'FIRM FIXED PRICE' suggests cost certainty for the government, but the overall value proposition depends on the negotiated price per dose relative to market rates and the public health impact achieved. Without more granular data on the specific vaccine and its market dynamics at the time of award, a definitive assessment of 'excellent' or 'good' value is difficult.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

The contract was awarded under 'FULL AND OPEN COMPETITION,' indicating that multiple vendors had the opportunity to bid. The number of bidders is not specified, but this competitive process is generally expected to foster price discovery and potentially lead to more favorable terms for the government. The effectiveness of this competition in driving down costs would depend on the number of qualified bidders and the specific requirements of the solicitation.

Taxpayer Impact: A full and open competition suggests that taxpayer dollars were likely used efficiently by leveraging market forces to secure the best possible price for the vaccine.

Public Impact

Beneficiaries include children across the United States who received the purchased vaccine, contributing to herd immunity and disease prevention. The service delivered is the procurement of a critical vaccine, ensuring its availability for public health programs. The geographic impact is national, covering all states and territories where the vaccine is distributed. Workforce implications are indirect, potentially supporting jobs within the pharmaceutical manufacturing and distribution sectors.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Lack of specific unit cost data makes it difficult to assess true value for money.
The 'DEFINITIVE CONTRACT' type, while providing certainty, could limit flexibility if market conditions change significantly.
Limited transparency on the number of bidders in the 'full and open competition' hinders a full assessment of competitive intensity.

Positive Signals

Awarded through 'full and open competition,' suggesting a robust bidding process.
The 'FIRM FIXED PRICE' contract type provides cost predictability for the government.
The substantial award amount indicates a significant commitment to a critical public health need.

Sector Analysis

This contract falls within the Healthcare sector, specifically the sub-sector of vaccine manufacturing and procurement. The pharmaceutical industry is characterized by high R&D costs, patent protections, and significant government involvement in public health initiatives. Federal spending on vaccines is a critical component of national health security, aimed at preventing and controlling infectious diseases. Comparable spending benchmarks would involve analyzing other large-scale federal procurements of vaccines or essential pharmaceuticals.

Small Business Impact

There is no indication from the provided data that this contract involved small business set-asides or significant subcontracting opportunities for small businesses. The nature of large-scale vaccine procurement typically involves major pharmaceutical manufacturers, which are generally large corporations. Further investigation would be needed to determine if any portion of the contract was specifically allocated to or flowed down to small businesses.

Oversight & Accountability

Oversight for this contract would typically fall under the Department of Health and Human Services (HHS) and its various components, such as the Centers for Disease Control and Prevention (CDC). Accountability measures would be embedded in the contract terms, including delivery schedules, quality standards, and payment milestones. Transparency is generally facilitated through contract databases like FPDS-NG, though detailed performance reports may not always be publicly accessible. Inspector General jurisdiction would apply to any potential fraud, waste, or abuse related to the contract.

Related Government Programs

HHS Vaccine Purchase Programs
CDC Public Health Initiatives
National Childhood Vaccine Injury Act
Pharmaceutical Manufacturing Contracts

Risk Flags

Potential for supply chain disruption if single-source issues arise.
Value for money assessment is difficult without granular unit cost data.
Contract duration and scope may limit flexibility in response to market changes.

Frequently Asked Questions

What is this federal contract paying for?

Department of Health and Human Services awarded $1.32 billion to MERCK SHARP & DOHME CORP.. TAS::75 0512::TAS PURCHASE OF VACCINE FOR CHILDREN

Who is the contractor on this award?

The obligated recipient is MERCK SHARP & DOHME CORP..

Which agency awarded this contract?

Awarding agency: Department of Health and Human Services (Centers for Disease Control and Prevention).

What is the total obligated amount?

The obligated amount is $1.32 billion.

What is the period of performance?

Start: 2007-04-16. End: 2008-06-01.

What was the specific vaccine purchased under this contract and what was its public health significance at the time?

The provided data does not specify the exact vaccine purchased under TAS::75 0512. However, the contract's value of over $1.3 billion suggests it was a significant procurement, likely for a widely used vaccine critical to public health. Given the award date of 2007-2008, potential candidates could include seasonal influenza vaccines, childhood immunizations like the pneumococcal conjugate vaccine (PCV), or vaccines addressing emerging public health concerns. The public health significance would be tied to its role in preventing disease, reducing hospitalizations, and contributing to population-level immunity, particularly among vulnerable groups such as children.

How does the awarded price compare to market rates for similar vaccines during the 2007-2008 period?

Without the specific vaccine identified and access to detailed market pricing data from 2007-2008, a direct comparison of the awarded price to market rates is not feasible. The contract's 'FIRM FIXED PRICE' of approximately $1.3 billion for a definitive contract awarded to Merck suggests a negotiated price per unit. To assess value for money, one would need to research the prevailing wholesale acquisition cost (WAC) or average manufacturer price (AMP) for comparable vaccines during that timeframe and calculate the implied per-unit cost from the total contract value. Factors like bulk purchasing discounts, contract duration, and specific formulation could influence the final price.

What were the key performance indicators (KPIs) and deliverables outlined in this contract?

The provided data snippet does not detail the specific Key Performance Indicators (KPIs) or deliverables for this contract. However, for a vaccine procurement contract of this magnitude, typical KPIs would likely include timely delivery of vaccine doses meeting specified quality and efficacy standards, adherence to cold chain requirements during transport and storage, and potentially reporting on distribution logistics. Deliverables would primarily be the vaccine doses themselves, along with associated documentation such as certificates of analysis and lot release information, ensuring compliance with FDA regulations and CDC requirements.

What is the track record of Merck Sharp & Dohme Corp. in fulfilling large federal vaccine contracts?

Merck Sharp & Dohme Corp. (MSD) has a long-standing and significant track record in developing, manufacturing, and supplying vaccines globally, including to the U.S. federal government. They are known for producing a wide range of vaccines, including those for childhood immunization schedules (e.g., MMR, Varicella), HPV (Gardasil), and pneumococcal disease. Historically, Merck has been a key partner in federal vaccination programs, often securing large contracts through competitive bidding processes. Their extensive experience in navigating regulatory requirements, large-scale manufacturing, and complex supply chains suggests a generally reliable capacity to fulfill substantial government vaccine procurements.

How did the 'full and open competition' process influence the final contract price and terms?

A 'full and open competition' process is designed to maximize the number of potential bidders, thereby fostering a competitive environment that theoretically drives down prices and improves terms for the government. For this $1.3 billion vaccine contract, the open competition likely encouraged Merck to submit its most competitive offer. The extent to which it influenced the final price depends on the number of qualified bidders, the specific technical requirements, and the government's evaluation criteria. While the 'FIRM FIXED PRICE' suggests a negotiated outcome, the competitive pressure aims to ensure this price reflects market realities and offers good value.

What are the potential risks associated with a large, single-award definitive contract for vaccine procurement?

A significant risk associated with a large, single-award definitive contract, such as this $1.3 billion vaccine procurement, is vendor lock-in and potential supply chain vulnerability. If Merck were to face manufacturing issues, quality control problems, or unexpected cost increases, the government's ability to pivot to an alternative supplier quickly could be limited due to the definitive nature of the contract. This could lead to potential shortages or delays in vaccine availability. Additionally, over-reliance on a single supplier might reduce leverage in future negotiations if market conditions change or new, more cost-effective vaccines become available.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Biological Product (except Diagnostic) Manufacturing

Product/Service Code: CHEMICALS AND CHEMICAL PRODUCTS

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Solicitation ID: 2007N09211

Offers Received: 1

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Parent Company: Merck & CO., Inc. (UEI: 054554290)

Address: 770 SUMNEY TOWN PIKE, WEST POINT, PA, 19486

Business Categories: Category Business, Not Designated a Small Business

Financial Breakdown

Contract Ceiling: $2,430,724,043

Exercised Options: $2,430,724,043

Current Obligation: $1,317,743,050

Contract Characteristics

Commercial Item: COMMERCIAL ITEM

Timeline